Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.
about
The role of genetic variation near interferon-kappa in systemic lupus erythematosusRheumatologic manifestations of sarcoidosisParadoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overviewThe Lymphotoxin Network: orchestrating a type I interferon response to optimize adaptive immunityFamilial aggregation of autoimmune disease in juvenile dermatomyositisBrief Report: IRF5 systemic lupus erythematosus risk haplotype is associated with asymptomatic serologic autoimmunity and progression to clinical autoimmunity in mothers of children with neonatal lupusAssociation of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohortThe detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.Genetic regulation of serum cytokines in systemic lupus erythematosusRegulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatmentA distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNsLinkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestryLigation of TLR5 promotes myeloid cell infiltration and differentiation into mature osteoclasts in rheumatoid arthritis and experimental arthritis.Type 1 interferons and myositis.Local expression of tumor necrosis factor-receptor 1:immunoglobulin G can induce salivary gland dysfunction in a murine model of Sjögren's syndrome.Lymphotoxin-LIGHT pathway regulates the interferon signature in rheumatoid arthritis.Cytokines in Sjogren's syndrome: potential therapeutic targets.Novel aspects of Sjögren's syndrome in 2012.Mechanisms of tumor necrosis factor α antagonist-induced lupus in a murine model.Genetic analysis of the pathogenic molecular sub-phenotype interferon-alpha identifies multiple novel loci involved in systemic lupus erythematosus.Concomitant detection of IFNα signature and activated monocyte/dendritic cell precursors in the peripheral blood of IFNα-treated subjects at early times after repeated local cytokine treatments.Chitinases in the salivary glands and circulation of patients with Sjögren's syndrome: macrophage harbingers of disease severity.Aspects of innate immunity in Sjögren's syndrome.B lymphocyte stimulator levels in systemic lupus erythematosus: higher circulating levels in African American patients and increased production after influenza vaccination in patients with low baseline levels.Drug-induced granulomatous interstitial nephritis in a patient with ankylosing spondylitis during therapy with adalimumab.Analysis of Associations of Human BAFF Gene Polymorphisms with Autoimmune Thyroid Diseases.Type I and II interferon signatures in Sjogren's syndrome pathogenesis: Contributions in distinct clinical phenotypes and Sjogren's related lymphomagenesis.Large-scale analysis of tumor necrosis factor α levels in systemic lupus erythematosusThe type I interferons: Basic concepts and clinical relevance in immune-mediated inflammatory diseases.The PTPN22 C1858T polymorphism is associated with skewing of cytokine profiles toward high interferon-alpha activity and low tumor necrosis factor alpha levels in patients with lupusSerum type I interferon activity is dependent on maternal diagnosis in anti-SSA/Ro-positive mothers of children with neonatal lupus.Increased serum type I interferon activity in organ-specific autoimmune disorders: clinical, imaging, and serological associations.Off-label uses of anti-TNF therapy in three frequent disorders: Behçet's disease, sarcoidosis, and noninfectious uveitis.Exposure to nuclear antigens contributes to the induction of humoral autoimmunity during tumour necrosis factor alpha blockade.Elevated serum interferon-alpha activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty-six months of therapy.Developments in the scientific and clinical understanding of inflammatory myopathies.Systemic and local interleukin-17 and linked cytokines associated with Sjögren's syndrome immunopathogenesisLong interspersed nuclear elements (LINE-1): potential triggers of systemic autoimmune disease.Type I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.Type I interferon in organ-targeted autoimmune and inflammatory diseases.
P2860
Q21296846-D489F7F5-32F8-4386-8919-C35CE16E3AF7Q24608644-96415379-E10A-4735-9E05-45EAA57597E0Q26738918-F9AFCE0A-0EBC-44C4-9296-660C133927FBQ27025082-9013C619-7D3A-4FBB-9DD8-E60701AEF367Q28235854-0102BFC3-9A91-479E-903E-EDEFA97F16E6Q28268287-3FD00B92-D435-4859-8D19-880CBEC4CE88Q28271779-C38CBCE3-2DE7-4FE7-9F7D-FE11033EAAB9Q30497355-C5A71AAD-FE57-4110-A4B8-CEAEE34ED0B4Q33682879-502EED4D-851D-463C-BBAB-69386494E0A6Q33873657-A223A164-4F7E-4A52-9F23-76D09EEC5FC3Q34089816-783CBD0D-F389-4491-87B6-B00C552E78E1Q34110737-ECC2F4E1-1300-4678-A501-A019A31D0907Q34289171-3EB2CC5F-BE81-467D-AA69-599DDA48DAC2Q34350190-F1F2C62D-82DE-4E07-9AB9-C77B234180D6Q34413324-A661CDFE-F460-4A22-B90F-B566DB4E93BBQ34535634-957655BF-E0DB-4E87-BBCC-32156A231862Q34601660-08FE3CDF-37A9-4DF1-A0C5-B2BFCABA134EQ34650103-4DD2BDE6-B6BD-4887-A160-740E259CFB65Q34790990-52DFE39A-0E5F-4589-87A7-6D94644DA75FQ35008001-009A7F17-7D7E-4904-ADDA-B86894925BA4Q35047686-D24F2982-5523-4E81-B908-BC6F691016AEQ35242525-87C1FCD3-A9AB-4511-A478-F1FCB6BAA3BBQ35557792-0E0A691E-6643-4E88-A27F-C45D5599773AQ35602526-85B15951-95F9-484E-B348-FFF30BB0475CQ35852535-FC8FA296-3211-4246-8FAC-F214B3BE3767Q36005239-32AE92CF-546D-4063-8AB4-E6B684B91151Q36042432-A9BFCD32-DFD1-41EC-AA3A-13ACC4F16D39Q36095071-EA926FFC-0180-49A0-9D4B-4A80AF59F8C2Q36338717-340E4D40-CDFD-4ECE-9B64-95237CF4FE92Q37052133-12EEBA7A-1893-4DD9-B2A7-01040CA371CDQ37073744-1871C444-7DD7-4287-861B-5BDFA64BF085Q37103639-C1D0ACA7-86C8-49D9-B494-EE4FA1D2D6C4Q37105146-AA146FD1-685A-4CA4-9B09-2E2265F6E2C5Q37191438-1E9B71EF-D2C7-41DE-8C32-C424129448A0Q37229729-249569A3-E55A-4241-8DA4-0CFFBB103754Q37306840-4C9023AF-692C-4FA6-81D6-CD8586F671B9Q37316528-B262F958-A4FE-46E9-9B86-B07043B6D4B5Q37644507-2885C439-DD27-448D-8C3B-C4BAE9829E4AQ37808291-BD597432-2BE8-4EBE-959E-656CDAC322F9Q37838003-6DF20264-B4AC-43CC-9FD8-B6435E942ADD
P2860
Augmented interferon-alpha pathway activation in patients with Sjögren's syndrome treated with etanercept.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on December 2007
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Augmented interferon-alpha pat ...... drome treated with etanercept.
@en
Augmented interferon-alpha pat ...... drome treated with etanercept.
@nl
type
label
Augmented interferon-alpha pat ...... drome treated with etanercept.
@en
Augmented interferon-alpha pat ...... drome treated with etanercept.
@nl
prefLabel
Augmented interferon-alpha pat ...... drome treated with etanercept.
@en
Augmented interferon-alpha pat ...... drome treated with etanercept.
@nl
P2093
P2860
P356
P1476
Augmented interferon-alpha pat ...... drome treated with etanercept.
@en
P2093
Clio P Mavragani
Mary K Crow
Niki M Moutsopoulos
Sharon M Wahl
Stanley R Pillemer
P2860
P304
P356
10.1002/ART.23062
P577
2007-12-01T00:00:00Z